Experience

Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology

December 23, 2024

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Rama Padmanabhan
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Asa Henin
Partner, San Diego
Matthew D. Silverman
Special Counsel, Santa Monica
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Jiqiang Lin
Associate, New York
Leina Verrier
Associate, Santa Monica
Ross Eberly
Partner, Santa Monica
Stephanie Gentile
Partner, New York
Christopher Kimball
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jean Park
Partner, New York
Aaron Pomeroy
Partner, Colorado
Michelle Garcia Schulman
Partner, Reston
Ellie Seber
Partner, Santa Monica
Marty Schenker
Senior Counsel , San Francisco
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Ajay Athavale
Associate, San Francisco
Rajdeep Roger Bains
Associate, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
Elizabeth Caruso
Associate, New York
Adrienne Beaudoin Deshmukh
Associate, Reston
Jeremy M. Exelbert
Associate, New York
Daniel Gillon
Associate, San Diego
Zack Gong
Associate, Shanghai
Rick Jantz
Associate, Santa Monica
Wyatt Kernell
Associate, Colorado
Rebeca Kinslow
Associate, San Diego
Hilda Li
Associate, Hong Kong
Lunga Su
Associate, Shanghai
Novak Topalovic
Associate, San Diego
Tania Soris
Associate, New York
Christine Tse
Associate, New York
Monica Xu
Special Counsel, Shanghai
Sai Yarramalla
Associate, Palo Alto
Andy Zachrich
Associate, San Francisco
Zheng Zhou
Associate, Palo Alto
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York

Related Practices & Industries

Tvardi Therapeutics Announces Merger With Cara Therapeutics

December 18, 2024

 

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.

Read more

Related contacts

Div Gupta
Partner, New York
Rama Padmanabhan
Partner, San Diego
Carlos Ramirez
Partner, San Diego
Matthew D. Silverman
Special Counsel, Santa Monica
Anitha Anne
Special Counsel, San Francisco
Lindsey O'Crump
Associate, Washington, DC
Brittany K. Wightman
Associate, San Diego
Michael Bergmann
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Lila Hope
Partner, Palo Alto
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Howard Morse
Senior Counsel, Washington, DC
Francis Wheeler
Senior Counsel, Colorado
Natasha Leskovsek
Of Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Reid Hooper
Special Counsel, Washington, DC
Justin Kisner
Special Counsel, Palo Alto
Dani Nazemian
Special Counsel, San Diego
Stella Sarma
Partner, Brussels
Karen Tsai
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Elizabeth Caruso
Associate, New York
Navya Dasari
Associate, New York
Jeremy Gentile
Associate, San Diego
Carly E. Gibbons
Associate, Chicago
Rachel F. Katz
Special Counsel, New York
Wyatt Kernell
Associate, Colorado
Jiqiang Lin
Associate, New York
Kelly McCormick
Associate, San Francisco
Jonathan Perez-Reyzin
Associate, San Diego
Carly Robinson
Associate, Reston
Jesse Schulman
Associate, Colorado
Rebecca Siegel
Associate, San Francisco
Tania Soris
Associate, New York
Dionne A. Thomas
Associate, San Diego
Christine Tse
Associate, New York
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York
Brian Mitchell
Transactional Quantitative Analyst, San Diego

Related Practices & Industries

Flare Therapeutics Announces Strategic Discovery Collaboration With Roche, Potentially Exceeding $1.8 Billion

November 20, 2024

Cooley advised Flare Therapeutics, a clinical-stage biotechnology company, on its strategic discovery collaboration with Roche.

Read more

Related contacts

Dr. Kate Hillier
Partner, Palo Alto
Christophe Beauduin
Partner, New York
Jiqiang Lin
Associate, New York
Jameson Davis
Associate, Boston
Jonathan Kaufman
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Rachel Thorn
Partner, New York

Related Practices & Industries

Foreseen Biotechnology Announces Exclusive Global Licensing Agreement With Ipsen

July 11, 2024

Cooley advised Foreseen Biotechnology – an emerging biotech company that pioneered a high-throughput integrated translational proteomics platform powered by an artificial intelligence-based data analytical system to accelerate the discovery of novel targets for therapeutics and diagnostics that are clinically relevant – on its exclusive global licensing agreement with Ipsen for FS001, an antibody-drug conjugate with first-in-class potential.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Jiqiang Lin
Associate, New York
Robert Eisenbach
Of Counsel, San Francisco
Amanda Pacheco
Associate, Palo Alto
Xander Lee
Partner, Santa Monica
David Burns
Special Counsel, Washington, DC

Related Practices & Industries

Ochre Bio Announces Partnership With Boehringer Ingelheim

April 22, 2024

Cooley advised Ochre Bio, a UK-based pioneer in chronic liver disease medicine development with labs in New York and Taipei, on its partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases, such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Simon Amies
Partner, London
Aaron Pomeroy
Partner, Colorado
Frances Stocks Allen
Partner, London
Jiqiang Lin
Associate, New York
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

View more

Admissions and credentials

New York